Ng Y T, Ouvrier R A, Wu T
Department of Pediatrics, The New Children's Hospital, Westmead, Parramatta, NSW, Australia.
J Child Neurol. 1998 Mar;13(3):109-12. doi: 10.1177/088307389801300303.
A series of 33 patients with juvenile dermatomyositis was reviewed in terms of their prognosis in relation to their drug therapy. This retrospective study was intended to help clarify the use of various therapies in this rare, heterogeneous disease from our hospital's experience in the last 24 years. The results confirmed that oral corticosteroids should remain the undisputed first line of treatment. For more refractory, chronic patients, the results suggest that azathioprine should be the favored drug of first choice (in addition to corticosteroids). There may be a role for cyclosporine as a "rescue" treatment, but this needs to be further defined.
回顾了33例青少年皮肌炎患者的药物治疗预后情况。这项回顾性研究旨在根据我院过去24年的经验，帮助阐明在这种罕见的异质性疾病中各种治疗方法的使用。结果证实，口服糖皮质激素仍应是无可争议的一线治疗药物。对于更难治的慢性患者，结果表明硫唑嘌呤应是首选药物（除糖皮质激素外）。环孢素可能作为一种“挽救”治疗方法，但这需要进一步明确。
